{"filing":{"accession_number":"0001645113-26-000068","cik":"0001645113","ticker":"NVCR","company_name":"NovoCure Ltd","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-02","primary_document":"nvcr-20260902.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511326000068/nvcr-20260902.htm"},"events":[{"id":32169,"run_id":29551,"accession_number":"0001645113-26-000068","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Timothy Scannell, a current director of NovoCure Limited, retired from the Board effective September 2, 2026, with his seat formally vacated. This is a clear director departure disclosed under Item 5.02(b). While the filing notes the retirement was not due to disagreement, the departure of a board member is material to investors' assessment of governance and board composition.","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35280,"accession_number":"0001645113-26-000068","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Timothy Scannell, a current director of NovoCure Limited, retired from the Board effective September 2, 2026, with his seat formally vacated. This is a clear director departure disclosed under Item 5.02(b). While the filing notes the retirement was not due to disagreement, the departure of a board member is material to investors' assessment of governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:03:42.913001+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35280,"accession_number":"0001645113-26-000068","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Timothy Scannell, a current director of NovoCure Limited, retired from the Board effective September 2, 2026, with his seat formally vacated. This is a clear director departure disclosed under Item 5.02(b). While the filing notes the retirement was not due to disagreement, the departure of a board member is material to investors' assessment of governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:03:42.913001+00:00","company_name":"NovoCure Ltd","ticker":"NVCR","filing_date":"2026-09-09"}]}